Teva Pharmaceutical Industries (TEVA) Lowered to Underperform at Wells Fargo & Co

Wells Fargo & Co downgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a market perform rating to an underperform rating in a report published on Friday. They currently have $17.00 price objective on the stock, down from their prior price objective of $19.58.

A number of other research analysts also recently weighed in on TEVA. Citigroup raised Teva Pharmaceutical Industries from a neutral rating to a buy rating and set a $24.00 price objective on the stock in a research note on Thursday. Cantor Fitzgerald set a $18.00 price objective on Teva Pharmaceutical Industries and gave the company a hold rating in a research note on Wednesday. Leerink Swann started coverage on Teva Pharmaceutical Industries in a research note on Tuesday. They issued an underperform rating and a $15.00 price objective on the stock. Zacks Investment Research raised Teva Pharmaceutical Industries from a strong sell rating to a hold rating in a research note on Tuesday. Finally, UBS Group set a $20.00 price objective on Teva Pharmaceutical Industries and gave the company a hold rating in a research note on Monday, December 18th. Seven analysts have rated the stock with a sell rating, seventeen have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Teva Pharmaceutical Industries has a consensus rating of Hold and an average target price of $21.16.

Shares of Teva Pharmaceutical Industries (TEVA) opened at $19.22 on Friday. The stock has a market capitalization of $19,030.00, a PE ratio of -3.27, a PEG ratio of 1.39 and a beta of 0.54. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. Teva Pharmaceutical Industries has a 1-year low of $10.85 and a 1-year high of $37.94.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th were given a $0.085 dividend. This represents a $0.34 annualized dividend and a yield of 1.77%. The ex-dividend date of this dividend was Monday, November 27th. Teva Pharmaceutical Industries’s dividend payout ratio is currently -12.27%.

Hedge funds and other institutional investors have recently modified their holdings of the business. San Francisco Sentry Investment Group CA bought a new position in Teva Pharmaceutical Industries in the 2nd quarter worth approximately $106,000. Bronfman E.L. Rothschild L.P. increased its position in Teva Pharmaceutical Industries by 2.6% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after buying an additional 94 shares during the period. Penserra Capital Management LLC bought a new position in Teva Pharmaceutical Industries in the 3rd quarter worth approximately $129,000. Fieldpoint Private Securities LLC bought a new position in Teva Pharmaceutical Industries in the 3rd quarter worth approximately $171,000. Finally, Fayez Sarofim & Co. bought a new position in Teva Pharmaceutical Industries in the 2nd quarter worth approximately $204,000. 51.98% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Teva Pharmaceutical Industries (TEVA) Lowered to Underperform at Wells Fargo & Co” was originally posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://www.com-unik.info/2018/01/06/teva-pharmaceutical-industries-teva-lowered-to-underperform-at-wells-fargo-co.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit